WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2015120768) GPR142 AGONIST COMPOUNDS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2015/120768    International Application No.:    PCT/CN2015/071286
Publication Date: 20.08.2015 International Filing Date: 22.01.2015
IPC:
C07D 233/58 (2006.01), C07D 233/60 (2006.01), C07D 233/61 (2006.01), A61K 31/4164 (2006.01), A61K 31/4178 (2006.01), A61P 3/10 (2006.01)
Applicants: ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center Indianapolis, Indiana 46285 (US).
LILLY CHINA RESEARCH AND DEVELOPMENT CO., LTD. [CN/CN]; 780 Cailun Road, Rm.819, Zhangjiang High Technology Park Pudong New Area Shanghai 201203 (CN) (MG only)
Inventors: MA, Tianwei; (US).
ZENG, Mi Emily; (US).
HU, Zhi Long; (US).
LIU, Lian Zhu; (US).
ZHOU, Jingye; (US)
Agent: CHINA PATENT AGENT (H.K.) LTD.; 22/F., Great Eagle Center, 23 Harbour Road, Wanchai Hong Kong (CN)
Priority Data:
PCT/CN2014/072083 14.02.2014 CN
Title (EN) GPR142 AGONIST COMPOUNDS
(FR) COMPOSÉS AGONISTES DU GPR142
Abstract: front page image
(EN)The present invention provides compounds of the Formula (Ia) wherein R is selected from the group consisting of CH3, CH (CH3) 2, CH2CN, CH2CHF2, CH2CF3, (A), (B), (C), (D), (E), (F), CH2CH2OCH3, and CH2C(O)OCH(CH3)2; R1 is selected from the group consisting of CF3, OCF3, and Cl; R2 is selected from the group consisting of H and F; or a pharmaceutically acceptable salt thereof.
(FR)La présente invention concerne des composés de formule (I) dans laquelle R est choisi dans le groupe consistant en CH3, CH (CH3) 2, CH2CN, CH2CHF2, CH2CF3, A, B, C, D, E, F, CH2CH2OCH3, et CH2C (O) OCH (CH3) 2; R1 est choisi dans le groupe consistant en CF3, OCF3, et Cl ; R2 est choisi dans le groupe consistant en H et F ; ou un sel pharmaceutiquement acceptable de ces composés.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)